Contract Deobligations Alert — August 01, 2026

Regeneron secured a $695.7 million cost-plus-fixed-fee contract from HHS/BARDA under full-and-open competition, providing stable margins and cost recovery through 2027. The contract represents ~$69.6M annual revenue with only $238.8M outlaid to date, suggesting significant remaining funding runway.

AT&T's $261.1 million delivery order for foreign post telephone systems ended March 2021, with only $27.3M outlaid. This mature contract provides no current or future revenue contribution and offers no insight into follow-on opportunities.

Lockheed Martin's $17.3M and $1.44M NASA contracts both ended in 2020 and 2023 respectively, representing negligible revenue for a $60B+ company. The sole-source award on the larger contract suggests incumbency but no current competitive pressure.

Regeneron's $695.7M BARDA contract has vague program description ('IGF::OT::IGF'), obscuring specific R&D milestones and deliverables. Execution risk is elevated if the program shifts priorities or faces technical hurdles in biodefense R&D.

This digest shows 71% of total obligation value ($695.7M) concentrated in a single Regeneron contract. The remaining three contracts are all completed, creating a false sense of sector activity—only one contract provides forward-looking investment insight.

The AT&T State Department contract ended in 2021 with only 10.5% of obligated funds outlaid ($27.3M of $261.1M), suggesting potential budget execution issues or program cancellation. This pattern could indicate risk for future State Department telecom awards.

Regeneron's competitive win under full-and-open competition for biodefense R&D signals potential for follow-on contracts or option exercises from BARDA, especially given pandemic preparedness priorities. The $456.9M remaining unfunded balance ($695.7M - $238.8M outlaid) represents a significant future revenue opportunity.

The $695.7M HHS/BARDA contract highlights growing civilian agency investment in biodefense R&D, a trend that could benefit other biotech firms with government contracts (e.g., Moderna, Pfizer). The 10-year performance period suggests sustained funding commitment.

The $695.7M Regeneron contract from HHS/BARDA dominates this digest, representing 71% of total obligation value. This signals sustained civilian agency investment in advanced medical countermeasures, with cost-plus pricing reducing contractor risk.

Three of four contracts (AT&T State Dept, two Lockheed Martin NASA awards) are completed or historical, offering zero ongoing revenue. This digest's aggregate signal strength is artificially low due to stale data.

{"entity" => "Regeneron Pharmaceuticals (REGN)", "reason" => "Holds $695.7M BARDA contract with $456.9M unfunded balance; key biodefense R&D exposure", "trigger" => "BARDA option exercise announcement or contract modification; quarterly outlay updates"}

{"entity" => "AT&T (T)", "reason" => "Completed $261M State Department contract with low outlay rate; potential follow-on opportunity or budget risk signal", "trigger" => "State Department RFP for foreign post telecommunications services"}

{"entity" => "Lockheed Martin (LMT)", "reason" => "Two historical NASA contracts ended; watch for recompetition of sole-source work at Ames Research Center", "trigger" => "NASA Ames re-compete announcement for PISCES or similar engineering services"}